![John P. Brennan](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
John P. Brennan
Nessuna posizione attualmente
Profilo
John P.
Brennan worked as a Senior Vice President-Technical Operations at Guilford Pharmaceuticals, Inc..
Mr. Brennan attended Philadelphia College of Pharmacy for his undergraduate degree.
Precedenti posizioni note di John P. Brennan
Società | Posizione | Fine |
---|---|---|
Guilford Pharmaceuticals, Inc.
![]() Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Direttore operativo | 03/10/2005 |
Formazione di John P. Brennan
Philadelphia College of Pharmacy | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
Guilford Pharmaceuticals, Inc.
![]() Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Health Technology |
- Borsa valori
- Insiders
- John P. Brennan